海思科：HSK45030分散片获国家药品监督管理局受理

Core Viewpoint - Company Haisco (002653) has received a Notice of Acceptance from the National Medical Products Administration for its drug HSK45030 dispersible tablets, aimed at treating muscular dystrophy [1] Group 1: Product Development - HSK45030 is a self-developed oral, selective small molecule inhibitor [1] - Preclinical studies indicate that HSK45030 significantly reduces muscle damage caused by excessive muscle contraction [1] - The drug has shown excellent efficacy in preventing muscle atrophy in animal models [1]